* Immix Biopharma Inc reported a quarterly adjusted loss of 24 cents per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -23 cents. The lone analyst forecast for the quarter was for a loss of 16 cents per share.
* Reported revenue was zero; analysts expected zero.
* Immix Biopharma Inc's reported EPS for the quarter was a loss of 24 cents.
* The company reported a quarterly loss of $7.15 million.
* Immix Biopharma Inc shares had risen by 15.4% this quarter and lost 75.1% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 23.8% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Immix Biopharma Inc is 7.00 This summary was machine generated from LSEG data November 13 at 03:53 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.16 -0.24 Missed
Jun. 30 2024 -0.21 -0.15 Beat
Dec. 31 2023 -0.23 -0.23 Met
Comments